TheTreatment of Acne Scar Using UltraPulse CO2 Laser

May 31, 2021 updated by: Kuo-Liang Cheng, Haute Beauté Skin & Vein Clinic

A Single-Blinded Split Face Prospective Study Comparing Different Energy, Efficacy, and Safety of UltraPulse CO2 Laser in the Treatment of Acne Scar Using Antera Quantitative 3D Image Analysis

Purpose of the study is to assess the effect and evaluate topographic volume changes of UltraPulse at treating boxcar scars with different energy and the effect of UltraPulse at treating icepick scars.

Study Overview

Status

Unknown

Conditions

Detailed Description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 24 hour screening period to determine eligibility for study entry. Upon enrollment, patient who fulfill all the inclusion criteria and does not fulfill any exclusion criteria will be scheduled for their visits.

All subjects will be receiving two sessions of treatment, with the two sessions 8-12 weeks apart. Subjects' face will be divided to left and right, with each side randomized to receive a low versus high energy setting. In the low energy setting side of the face, central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ. In the high energy setting side of the face, central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ. Subject will be blinded regarding which side of the face received low versus high energy setting.

Ultrasound will be used to assess epidermal and dermal thickness change at the treated area. This will be performed before the 1st and 2nd treatment session as well as one month and three month after the 2nd treatment session.

Antera Quantitative 3D Image Analysis will be performed before and after the 1st and 2nd treatment session as well as one month and three month after the 2nd treatment session.

3mm punch biopsy will be taken from 10 volunteers over bilateral face before the 1st treatment session and 3 month after the 2nd treatment session (total of 4 sample will be obtained in each volunteer). Skin specimen will be stained with hematoxylin and eosin as well as relevant stain for collagen and elastic fiber.

Clinical photograph will be taken before and after the 1st and 2nd treatment session as well as one month and three month after the 2nd treatment session. Two blinded board certified dermatologist will be asked to rate the improvement of acne scar by GSAAS according to the clinical photograph taken.

All subjects will be asked to rate their satisfaction regarding treatment response over each side of the face using a 0 to 10 point scale chart.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Taipei, Taiwan, 110
        • Recruiting
        • HAUTE BEAUTÉ Skin & Vein Clinic
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 56 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subjects have to be aged from 20 to 60 year-old
  • Subjects currently have an area of involvement approximately 2cm × 2cm on each side of the face over the temples or cheek bone area
  • Classified as mild to moderate acne scar according to global severity of facial acne scar (GSAAS) score
  • After evaluation by clinician, those subjects to be treated with "Lumenis"CO2 Laser System (UltraPulse) can benefit from this laser treatment
  • Subjects need to be fully functional and aware of the pros and cons of the study. Subject is capable to make self judgement and sign the inform consent under his/her own will
  • Others: Have fully understand about this study and is willing to cooperate with the instruction of the study

Exclusion Criteria:

  • Those who were known to have keloid formation
  • Those who have porphyria or known photosensitivity
  • Those who previously underwent laser therapy treatment or skin biopsy and have showed poor result or adverse effect
  • Those who were classified as "severe" according to GSAAS system
  • Those who have bleeding tendency
  • Those who present with clinical data suggesting abnormal platelet function or coagulation disorder (such as prolonged aPTT or PT)
  • Those that are currently taking anticoagulants or anti-platelet drugs
  • Those who are on aspirin or other NSAIDs
  • Those who have history of granulomatous or connective tissue disease
  • Female subjects with a positive pregnancy test
  • Women who refuse to stay on effective contraception or refuse pregnancy tests during the study
  • After evaluation by the clinician, those that have been enrolled in clinical studies over the past 6 months that may alter the current study result
  • After evaluation by the clinician, those currently or had previous treatment of atrophic acne scars with fillers, lasers, deep chemical peels, or any other medical or surgical treatment which in the investigators' opinion could alter the results of the current clinical study
  • Those that are currently taking photo-sensitive drugs, oral isotretinoin, iron supplement or other herbal medication
  • Those that have received laser treatment over the lesion area over the past 3 months
  • Those that are currently pregnant or breastfeeding
  • After evaluation by the clinician, and concluded underline epilepsy, area to be treated is under infection or ulceration, poor wound healing)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: High energy
Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
Half of the face that receives low energy, their central base of boxcar scar will be treated with 30mJ, while shoulder of scar will be treated with 60 mJ
Other: Low energy
Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ
Half of the face that receives low energy, their central base of boxcar scar will be treated with 20mJ, while shoulder of scar will be treated with 50 mJ

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Topographic volume changes of acne scars from baseline one month and three month after the 2nd treatment session
Time Frame: from baseline one month and three month after the 2nd treatment session
Topographic volume changes of acne scars from baseline one month and three month after the 2nd treatment session
from baseline one month and three month after the 2nd treatment session
Histological change in epidermal/dermal component including elastic fiber and collagen synthesis three month after the 2nd treatment session from baseline
Time Frame: three month after the 2nd treatment session from baseline
Histological change in epidermal/dermal component including elastic fiber and collagen synthesis three month after the 2nd treatment session from baseline
three month after the 2nd treatment session from baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Access improvement of acne scar by Scale for global severity of facial acne scar from baseline one month and three month after the 2nd treatment session in both the low and high energy treated arm
Time Frame: from baseline one month and three month after the 2nd treatment session
Access improvement of acne scar by Scale for global severity of facial acne scar from baseline one month and three month after the 2nd treatment session in both the low and high energy treated arm. The minimum and maximum values of Scale for global severity of facial acne scar are 0 and 5, and higher scores mean a worse outcome.
from baseline one month and three month after the 2nd treatment session
Compare the difference of improvement of acne scar by Scale for global severity of facial acne scar in the low versus high energy treated arm
Time Frame: from baseline and three month after the 2nd treatment session
Compare the difference of improvement of acne scar by Scale for global severity of facial acne scar in the low versus high energy treated arm. The minimum and maximum values of Scale for global severity of facial acne scar are 0 and 5, and higher scores mean a worse outcome.
from baseline and three month after the 2nd treatment session
Compare the difference of newly synthesis collagen and elastic fiber through staining in the low versus high energy treated arm
Time Frame: from baseline and three month after the 2nd treatment session
Compare the difference of newly synthesis collagen and elastic fiber through staining in the low versus high energy treated arm
from baseline and three month after the 2nd treatment session
Assess the frequency and severity of encountered side effects in the low versus high energy treated arm
Time Frame: from baseline and three month after the 2nd treatment session
Assess the frequency and severity of encountered side effects in the low versus high energy treated arm
from baseline and three month after the 2nd treatment session
Subjects' satisfaction score rated in a 0 to 10 point scale
Time Frame: after the 2nd treatment session、one month and three month after the 2nd treatment session
Subjects' satisfaction score rated in a 0 to 10 point scale
after the 2nd treatment session、one month and three month after the 2nd treatment session

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Kuo-Liang Cheng, MD, HAUTE BEAUTÉ Skin & Vein Clinic

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 11, 2020

Primary Completion (Anticipated)

September 8, 2021

Study Completion (Anticipated)

November 28, 2021

Study Registration Dates

First Submitted

November 24, 2020

First Submitted That Met QC Criteria

December 1, 2020

First Posted (Actual)

December 2, 2020

Study Record Updates

Last Update Posted (Actual)

June 3, 2021

Last Update Submitted That Met QC Criteria

May 31, 2021

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acne Scar

Clinical Trials on High energy (UltraPulse)

Subscribe